e-therapeutics plc
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and automated evaluation; and GalOmic, a proprietary siRNA chemistry that generates potent and long-acting RNAi medicines. Its preclinical products are ETX-312 to trea… Read more
Market Cap & Net Worth: e-therapeutics plc (ETXPF)
e-therapeutics plc (PINK:ETXPF) has a market capitalization of $75.96 Million ($75.96 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #20574 globally and #7443 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying e-therapeutics plc's stock price $0.13 by its total outstanding shares 584334976 (584.33 Million).
e-therapeutics plc Market Cap History: 2020 to 2025
e-therapeutics plc's market capitalization history from 2020 to 2025. Data shows change from $134.40 Million to $75.96 Million (-12.43% CAGR).
e-therapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how e-therapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
238.88x
e-therapeutics plc's market cap is 238.88 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $134.40 Million | $601.10K | -$3.09 Million | 223.59x | N/A |
| 2021 | $330.15 Million | $435.30K | -$5.06 Million | 758.43x | N/A |
| 2022 | $140.24 Million | $641.42K | -$10.85 Million | 218.64x | N/A |
| 2023 | $75.96 Million | $475.00K | -$8.27 Million | 159.92x | N/A |
| 2024 | $75.96 Million | $318.00K | -$11.17 Million | 238.88x | N/A |
Competitor Companies of ETXPF by Market Capitalization
Companies near e-therapeutics plc in the global market cap rankings as of March 19, 2026.
Key companies related to e-therapeutics plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
e-therapeutics plc Historical Marketcap From 2020 to 2025
Between 2020 and today, e-therapeutics plc's market cap moved from $134.40 Million to $ 75.96 Million, with a yearly change of -12.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $75.96 Million | 0.00% |
| 2024 | $75.96 Million | 0.00% |
| 2023 | $75.96 Million | -45.83% |
| 2022 | $140.24 Million | -57.52% |
| 2021 | $330.15 Million | +145.65% |
| 2020 | $134.40 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of e-therapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $75.96 Million USD |
| MoneyControl | $75.96 Million USD |
| MarketWatch | $75.96 Million USD |
| marketcap.company | $75.96 Million USD |
| Reuters | $75.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.